MGC Diagnostics Corporation



PROVIDE UNMATCHED SERVICE AND SUPPORT

RELENTLESSLY MAKE IMPROVEMENTS

AND SOLVE UNMET NEEDS

Corporate Presentation March 2016

www.mgcdiagnostics.com

SAFE HARBOR STATEMENT

From time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forward–looking statements concerning possible or anticipated future financial performance, business activities or plans that include the words "believes," "expects," "anticipates," "intends" or similar expressions. For these forward–looking statements, the Company claims the protection of the safe harbor for forward–looking statements contained in federal securities laws. These forward-looking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC, that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forward–looking statements. For a list of these factors, see the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements," in the Company's Form 10-K for the year ended October 31, 2015, and any updates in subsequent filings on Form 10-Q or Form 8-K under the Securities Exchange Act of 1934.

OUR IDENTITY

MGC Diagnostics Corporation is a global medical technology company dedicated to **CardioRespiratory health solutions**.




Conducting business through its wholly owned subsidiaries **Medical Graphics Corporation** (St. Paul, MN) and **Medisoft SA** (Sorinnes, Belgium)



Direct Management in Asia-Pacific, Latin America and Western Europe

OUR HISTORY



WHAT WE DO AND WHY

MGC Diagnostics **designs**, markets and sells non-invasive CardioRespiratory diagnostic capital equipment, accessories, supplies and services to healthcare providers specializing in COPD, asthma, and CardioRespiratory disease management.

According to the World Health Organization and the American Journal of Respiratory Care:

TO THE HOSPITAL



65 million people have COPD, accounting for 5% of all deaths globally increasing by >30% in the next 10 years to become the 3^{rd} leading cause of death worldwide*

The prevalence of COPD varies for a low of 3.9% of the population of MN to a high of 9.3% of the population of KY. COPD is the only major cause of death whose incidence is increasing.


300 MILLION CASES OF ASTHMA +33% BY 2025

300 million people have asthma, projected to increase to 400 million by 2025 - asthma is the most common disease in children*

WHAT WE DO AND WHY

• ASTHMA-COPD OVERLAP SYNDROME (ACOS):

is characterized by persistent airflow limitation with several features usually associated with asthma and several features usually associated with COPD.



Lung function testing is essential for the assessment of patients with suspected chronic disease of the airways. It must be performed at either the initial or a subsequent visit, if possible before and after a trial of treatment.

EXECUTIVE SUMMARY



Current diagnostic technologies are adequate to diagnose major diseases, however, existing products are underutilized*

The market is mature with a long product replacement lifecycle of 7-10 years.

Developments expected to stimulate future growth*

- Large and growing patient population with undiagnosed chronic disease
- Technology developments in diagnostic procedures that will optimize usage
 - Simplified technology
 - Centralized data
 - Patient-friendly
- Emerging device-based therapeutic options which will require discrete patient selection, hence, more discrete diagnosis
- The result may be increased annual growth and turnover rates in cardio-respiratory diagnostic products
 - Including Pulmonary Function, Gas Exchange and Spirometry and Respiratory-Pharma Clinical Trials


WHY MEDISOFT

ESTABLISH DIRECT GLOBAL OPERATIONS



Medisoft Business Partners

WHY MEDISOFT



WHY MEDISOFT

ENHANCED PRODUCT AND INTELLECTUAL PROPERTY PORTFOLIO

MGC DIAGNOSTICS

o 5 Product Categories

 PFT, BodyBox, Spirometry, Gas Exchange, Metabolic

O 10 Products

 PFT (2), Bodybox (2), Spirometry (1), Gas Exchange (3), Metabolic (2)

COMPETITOR

• 6 Product Categories

 PFT, BodyBox, Spirometry, Gas
 Exchange, Metabolic, Sleep Dx

O 20 Products

 PFT (3), BodyBox (4), Spirometry (5), Gas Exchange (4), Metabolic (2), Sleep Dx (2)

MEDISOFT

o 9 Product Categories

 PFT, BodyBox, Spirometry, Mechanics, Gas Exchange, Metabolic, eNO, ECG, Treadmill

O 27 Products

 PFT (4), BodyBox (3), Spirometry (5), Mechanics (3), Gas Exchange (3), Metabolic (3), eNO (2), ECG (1), Treadmill (3)

PERFORMANCE

FISCAL YEAR 2015 RESULTS



+24.9%

RECORD REVENUE Full year revenue increased 24.9% to \$37.5 million in fiscal 2015 compared to \$30.0 million in fiscal 2014.

OTHER HIGHLIGHTS

or (\$0.28) per diluted share

EBITDA \$2.6M vs. (\$209,000)

Backlog \$2.6M vs. \$1.9M

Operating Income \$1.6M vs. (\$811,000)

• Net Income \$4.0M, or \$0.94 per diluted share vs. (\$1.2M),

Deferred Revenue \$6.8M (current & long-term)

32% Attachment Rate for MGC domestic units sold

28% of equipment revenue came from new products

+11.6%


DOMESTIC GROWTH Our Medical Graphics subsidiary led the way with revenue growth in the U.S. of 11.6% to 32.0 million the best since fiscal year 2007

+13.2%


INTERNATIONAL GROWTH international revenue grew 13.2% to \$5.7 million, driven by stronger sales in Europe and the Asia/Pacific region.


- Renewed Global Visibility
 - International revenue increased 68% (full year of Medisoft)
 - Contributes 28% of total Revenue
 - Pacific-Medico Partnership

 Japanese Market
- o 66 Competitive Conversions
- 35% Recurring Revenue
- EU and Emerging Market Expansion, Adjacent Market, Differentiating Technology and Services




- MGC Diagnostics Corporation (NADAQ: MGCD) is a global medical technology company dedicated to CardioRespiratory Health Solution
- Operating in a capital equipment and recurring revenue model
- Significant recurring revenue model







REVENUE




BACKLOG

DEFERRED REVENUE








MANAGEMENT INITIATIVES:

DRIVE NEW DEVICE REVENUE

- Accelerate replacement of legacy MGC systems
- Drive sales through Group Purchasing Organizations (GPO)
- Take market share from competition
- Refresh existing products and add new, innovative products
- Focus on opportunistic international markets





MANAGEMENT INITIATIVES:

MARKET SHARE BY CONVERSIONS

- Expand market share by converting competitive accounts by leveraging
 - o Ultima Series Redesign
 - Information Technology
 Offerings
 - Best in Class Support

SERVICE AND REVENUE MARGINS





MANAGEMENT INITIATIVES:

INCREASE SERVICE CONTRACTS

- Pre-paid service agreement margins significantly outperform time and material agreements and provide greater margin consistency
- Service contract Attachment Rate has grown from 6% in FY12 to 32% in FY15

SUPPLIES REVENUE AND MARGINS




Supplies Revenue

MANAGEMENT INITIATIVES:

INCREASE SUPPLY USAGE: RECURRING REVENUE


 Leverage new and existing distribution partners world-wide

 Internal sales focus on customers that have historically purchased few supplies from us



OPERATING EXPENSE INITIATIVES


Operating Expenses (as a % of Revenue)



MANAGEMENT INITIATIVES:

- Operating expenses are in alignment with our current growth plan
- Operating expense leverage will occur as we grow future revenues

GROSS MARGINS




Gross Margins

MANAGEMENT INITIATIVES:

INCREASE GROSS MARGINS

- Grow equipment revenue to leverage our fixed production costs
- Grow higher margin recurring revenues (supplies and service)
- Streamline manufacturing processes to lower production costs
- Value engineer our products to lower costs and maintain quality

NET INCOME/LOSS



	1/31/14	10/31/14*	10/31/15	1/31/16
Cash and equivalents	\$11.1M	\$5.7M	\$6.6M	\$6.6M
Total assets	\$24.9M	\$32.3M	\$35.6M	\$35.4M
Total liabilities	\$9.2M	\$16.8M	\$15.7M	\$15.3M
Net working capital	\$15.1M	\$9.8M	\$11.4M	\$11.5M
Bank debt		\$3.8M	\$3.0M	\$2.8M
Shareholders equity	\$15.7M	\$15.5M	\$19.9M	\$20.1M
Shares outstanding	4.1M	4.2M	4.3M	4.3M

INVESTMENT HIGHLIGHTS

- Record Fiscal 2015 Financial Results
- Increased Global Opportunity Acquired Medisoft August 2014
- Recurring services/supplies revenues allow for greater predictability of revenue streams
- Key Growth Drivers
 - Aging Population
 - Global Market Opportunities
 - Conversion of Legacy Equipment
 - Conversion of Competitive Accounts
- Best-in-class customer base, products and service
- Strong product offerings in significant addressable markets
- Strong balance sheet with \$6.6 million in cash
- Success to date in gaining market share from competitors

LONG RANGE PLAN

In recent months the Board of Directors and the Company's management team have initiated a new Long-Term Strategic Plan focusing on process improvements throughout the enterprise to generate consistent growth and profitability in the coming years. We have a strong transformational vision of how we want MGC Diagnostics to develop and operate in the coming years. Our plan is built around six key initiatives:



MGC Diagnostics Corporation



www.mgcdiagnostics.com